Clinical Trials

Current Clinical Research Projects at our Clinic

Alector Inc.

INVOKE-2

Protocol: AL002-2

Patients: 50-85 years old

Diagnostic: Early Alzheimer’s disease

Agent: AL002

Intravenous Administration Every 4 Weeks

Enrollment: OPEN

Alzheon Inc.

APOLLOE4

Protocol: ALZ-801-AD301

Patients: 50-80 years old

Diagnostic: Early Alzheimer’s disease

Agent: ALZ-801

Twice Daily Oral Administration

Enrollment: OPEN

Athira Pharma Inc.

Lift AD

Protocol: ATH-1017-AD-0201

Patients: 55-85 years old

Diagnostic: Probable Mild-Moderate AD

Agent: ATH-1017

Daily Subcutaneous Injection

Enrollment: OPEN

Athira Pharma Inc.

SHAPE Trial

Protocol: ATH-1017-PD-0201

Patients: 40-85 years old

Diagnostic: Parkinson’s or Lewy Body disease

Agent: ATH-1017

Daily Subcutaneous Injection

Enrollment: OPEN

Cassava Sciences Inc.

RefocusALZ

Protocol: PTI-125-06

Patients: 50-87 years old

Diagnostic: Alzheimer’s disease (Stage 4 or 5)

Agent: Simufilam (PTI-125)

Twice Daily Oral Administration

Enrollment: OPEN

Eli Lilly and Company

TRAILBLAZER-ALZ3

Protocol: I5T-MC-AACM

Patients: 55-80 years old

Diagnostic: Prodromal/Asymptomatic AD

Agent: Donanemab

Intravenous Administration Every 4 Weeks

Enrollment: OPEN

Novo Nordisk

EVOKE Plus

Protocol: NN6535-4725

Patients: 55-85 years old

Diagnostic: Early Alzheimer’s disease

Agent: Semaglutide

Once Daily Oral Administration

Enrollment: OPEN

Novo Nordisk

EVOKE

Protocol: NN6535-4730

Patients: 55-85 years old

Diagnostic: Early Alzheimer’s disease

Agent: Semaglutide

Once Daily Oral Administration

Enrollment: OPEN

Athira Pharma Inc.

Act AD

Protocol: ATH-1017-AD-0202

Patients: 55-85 years old

Diagnostic: Probable Mild-Moderate AD

Agent: ATH-1017

Daily Subcutaneous Injection

Enrollment: Closed

Eli Lilly and Company

TRAILBLAZER-ALZ2

Protocol: I5T-MC-AACI

Patient: 60-85 years old

Diagnostic: Prodromal or Mild AD Dementia

Agent: Donanemab

Intravenous Administration Every 4 Weeks

Enrollment: Closed

TauRx Therapeutics Ltd.

LUCIDITY

Protocol: TRx-237-039

Patients: <90 years old

Diagnostic: MCI/Early Alzheimer’s disease

Agent: TRx0237

Daily Oral Administration

Enrollment: Closed

Contact Us